Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
15-12G - Research Alliance Corp. II (0001819724) (Filer)
25-NSE - Research Alliance Corp. II (0001819724) (Subject)
8-K - Research Alliance Corp. II (0001819724) (Filer)
Research Alliance Corp. II (the "Company") (NASDAQ:RACB), a special purpose acquisition company, today announced that, the Company will redeem all of its outstanding shares of Class A Common Stock, par value $0.0001, issued by the Company in its initial public offering (the "Public Shares"), effective as of the close of business on December 2, 2022, if at the Company's Special Meeting on December 2, 2022 the requisite stockholders of the Company approve (the "Stockholder Approval") the proposed amendment to the Company's Amended and Restated Certificate of Incorporation (the "Charter Amendment") and the proposed amendment to that certain Investment Management Trust Agreement, dated March 17
Globally focused radiopharmaceutical company achieves significant milestone to accelerate the operationalization of their 80,000 sq ft radioligand manufacturing facility POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, announced today that the U.S. Nuclear Regulatory Commission (NRC) has issued a Materials License for its new production facility located in Indianapolis, Indiana. POINT is currently finishing renovations to its 80,000-square-foot radiopharmaceutical manufacturing center which, when complete, will make it one of the largest, state-of-the-art, Good Manufacturing Practices (
LAS VEGAS--(BUSINESS WIRE)--Research Alliance Corp. II (Nasdaq:RACB) (the “Company”) announced today that on March 22, 2021 it closed its initial public offering of 14,950,000 shares of Class A common stock, including 1,950,000 shares issued pursuant to the exercise by the underwriters of their over-allotment option. The offering was priced at $10.00 per share, resulting in gross proceeds of $149,500,000. The Company, sponsored by RA Capital Management, L.P., is led by Chairman and CEO Peter Kolchinsky PhD, CIO Matthew Hammond, PhD and CFO Tess Cameron. The Company is a blank check company formed for the purpose of effecting a business combination with one or more businesses in the
4 - Research Alliance Corp. II (0001819724) (Issuer)
4 - Research Alliance Corp. II (0001819724) (Issuer)
3 - Research Alliance Corp. II (0001819724) (Issuer)
SC 13G/A - Research Alliance Corp. II (0001819724) (Subject)
SC 13G/A - Research Alliance Corp. II (0001819724) (Subject)
SC 13G/A - Research Alliance Corp. II (0001819724) (Subject)